ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy
Open Access
- 1 January 2020
- journal article
- review article
- Published by Elsevier BV in ESMO Open
- Vol. 5 (3), e000662
- https://doi.org/10.1136/esmoopen-2019-000662
Abstract
During the last years, there has been a dramatic increase in the administrative and bureaucratic burden associated with clinical research, which has clearly had an impact on its overall efficiency and on the activity of clinical investigators and research teams. Indeed, the supervision of the adherence of clinical research to Good Clinical Practice (GCP) guidelines and legal regulations is of the utmost importance. Yet, while such regulations have remained largely unchanged during recent years, the number of administrative tasks and their complexity have grown markedly, as supported by the results of a survey performed among 940 clinical investigators that we report in this manuscript. Therefore, many investigators believe that it has become necessary to undertake a rigorous analysis of the causes and consequences of this issue, and to create a conduit to channel the advice from experienced investigators regarding clinical research procedures, in order to improve them. Based on these premises, ESMO has launched the ESMO Clinical Research Observatory (ECRO), a task force that will analyse different aspects of clinical research. ECRO will aim to provide the views of ESMO on clinical research procedures based on the feedback from clinical investigators, under complete adherence to the Declaration of Helsinki, the GCP guidelines and any other applicable legal regulations, while at the same time showing profound respect for all the stakeholders involved in clinical research. This manuscript provides the background and rationale for the creation of ECRO, its planned activity and an analysis of the current administrative burden in clinical research with recommendations to rationalise it. Indeed, we expect that this effort shall lead to a relevant improvement in the care of patients and in the development of clinical research.This publication has 13 references indexed in Scilit:
- Re-Evaluating Eligibility Criteria for Oncology Clinical Trials: Analysis of Investigational New Drug Applications in 2015Journal of Clinical Oncology, 2017
- Modernizing Clinical Trial Eligibility: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research Minimum Age Working GroupJournal of Clinical Oncology, 2017
- Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research StatementJournal of Clinical Oncology, 2017
- Thoracic Oncology Clinical Trial Eligibility Criteria and Requirements Continue to Increase in Number and ComplexityJournal of Thoracic Oncology, 2017
- A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD GroupAnnals of Oncology, 2017
- Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patientsESMO Open, 2017
- The challenge of molecular testing for clinical trials in advanced non-small cell lung cancer patients: Analysis of a prospective databaseLung Cancer, 2016
- Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?Journal of Thoracic Oncology, 2016
- Lung cancer at the intensive care unit: The era of targeted therapyLung Cancer, 2015
- Impact of Cancer Research Bureaucracy on Innovation, Costs, and Patient CareJournal of Clinical Oncology, 2014